Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733449 | 0.89 | LMNA (0.37) | ALDH1A1MAPTL3MBTL1KDM4EFABP4 | |
| SCHEMBL29384926 | 0.89 | LMNA (0.37) | ALDH1A1MAPTL3MBTL1KDM4EFABP4 | |
| SCHEMBL25339260 | 0.85 | LMNA (0.34) | ALDH1A1MAPTL3MBTL1KDM4EFABP4 | |
| SCHEMBL25982013 | 0.79 | ALDH1A1 (0.42) | ALDH1A1ADORA2AMAPTL3MBTL1KDM4E | |
| SCHEMBL25982121 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ADORA2AMAPTPYCR1KMT2A | |
| SCHEMBL31234941 | 0.76 | PIK3CD (0.39) | ALDH1A1MAPTKDM4EFABP4TP53 | |
| SCHEMBL21734048 | 0.75 | PIK3CD (0.42) | ALDH1A1MAPTL3MBTL1KDM4EFABP4 | |
| SCHEMBL31196081 | 0.75 | PIK3CA (0.37) | ALDH1A1MAPTL3MBTL1KDM4EFABP4 | |
| SCHEMBL21722225 | 0.75 | ALDH1A1 (0.45) | ALDH1A1ADORA2AMAPTL3MBTL1PYCR1 | |
| SCHEMBL25065874 | 0.74 | MAPT (0.45) | ALDH1A1ADORA2AMAPTL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | ALDH1A1 3225/4885ADORA2A 3164/4885ERAP1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.